
If you’ve heard that one medicine acts on GLP-1 and another acts on GLP-1 and GIP, you might wonder what that extra signal does. Both names refer to hormones your gut releases in response to food. The difference between the medicines starts with which receptors they activate.
In this article
What GLP-1 and GIP do after a meal
GLP-1 stands for glucagon-like peptide-1. GIP stands for glucose-dependent insulinotropic polypeptide. Both are incretins, which are gut hormones that help the pancreas release insulin when glucose rises. Insulin helps cells take up glucose from the blood. GLP-1 also helps regulate appetite and can affect how fast the stomach empties. Human incretin research and semaglutide prescribing information.
Researchers can hold blood sugar at a set level to compare how the pancreas responds to each hormone. In one small experiment, the insulin response to infused GIP was weaker in adults with type 2 diabetes than in the comparison group without diabetes. That result describes a response to the natural hormone under controlled conditions. A trial of tirzepatide asks a different question about a medicine that activates both receptors. Nauck and colleagues, methods and results.
Which receptors semaglutide and tirzepatide activate
A receptor is a protein that receives a signal. A medicine called a receptor agonist activates that receptor. Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GLP-1 receptor and the GIP receptor. Each medicine has one active ingredient, even when it acts at more than one receptor. Wegovy label, section 12 and Zepbound label, section 12.
What we know about appetite and the added GIP signal
The U.S. labels describe lower calorie intake with semaglutide and tirzepatide and point to appetite as a likely explanation. Zepbound’s label says studies outside human clinical trials suggest that GIP receptor activation may also play a role in how much people eat. Clinical studies of tirzepatide measure the effect of the whole medicine, so those outcomes can’t tell you how much of the appetite change comes from GIP alone. Zepbound prescribing information, sections 12 and 14.
Imagine seeing a diagram with one highlighted receptor on one side and two on the other. It answers “Where does the medicine act?” To answer “What happened to blood sugar or appetite?” look for a study that measured that outcome in people and check who took part. The number of highlighted receptors gives you no estimate of how much your appetite or blood sugar might change.
Why the exact product name matters
In the United States, Wegovy injection and tablets contain semaglutide and have weight management indications for eligible adults. Zepbound injection contains tirzepatide and has a weight management indication for eligible adults, as well as an indication for moderate to severe obstructive sleep apnea in adults with obesity. For a closer look at a different semaglutide product and its indications, see our Ozempic guide. Wegovy label and Zepbound label.
If you have questions about a prescription, bring the exact brand and form, your other medicines, and any changes you’ve noticed. Ask your prescriber or pharmacist what outcome they plan to monitor. Let them know if you use insulin or a sulfonylurea, since the labels warn of a higher risk of low blood sugar with these combinations. Bring up pregnancy plans or oral contraception because the precautions depend on the product. Zepbound safety and interactions and Wegovy safety and interactions.
Frequently asked questions
Is GIP the same hormone as GLP-1?
They are distinct gut hormones with their own receptors. Both help coordinate the insulin response to food.
Does tirzepatide contain two medicines?
Tirzepatide is one active ingredient that activates two types of receptor, GIP and GLP-1.
Can a receptor diagram predict my response?
A diagram shows where a medicine acts. Clinical studies measure what happened in a defined group. Your clinician can explain which outcome is relevant to your care and how it will be monitored.


